Royalty Pharma (RPRX) Non-Current Assets (2019 - 2026)

Royalty Pharma has disclosed Non-Current Assets across 8 years of filings, most recently posting $18.4 billion for Q1 2026.

• Non-Current Assets for Q1 2026 came in at $18.4 billion, up 16.65% year-over-year; the trailing twelve-month figure through Mar 2026 was $70.8 billion (up 11.45% YoY), and the FY2025 annual result was $18.1 billion, up 10.18% from the prior year.
• Non-Current Assets came in at $18.4 billion for Q1 2026 at Royalty Pharma, up from $18.1 billion in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $18.4 billion in Q1 2026 to a low of $14.1 billion in Q3 2023.
• The 5-year median for Non-Current Assets is $15.1 billion (2023), against an average of $15.6 billion.
• Across the five-year window, Non-Current Assets slipped 7.85% in 2023 and increased 16.65% in 2026, its largest moves.
• Royalty Pharma's Non-Current Assets stood at $14.3 billion in 2022, then advanced by 5.96% to $15.1 billion in 2023, then advanced by 8.69% to $16.4 billion in 2024, then gained by 10.18% to $18.1 billion in 2025, then increased by 1.64% to $18.4 billion in 2026.
• The last three Non-Current Assets figures came in at $18.4 billion (Q1 2026), $18.1 billion (Q4 2025), and $17.5 billion (Q3 2025), per Business Quant data.